Alkem Laboratories Ltd. is an India-based pharmaceutical company engaged in the development, manufacturing, and sale of pharmaceutical products. The Company operates in a single business segment-Pharmaceuticals. It produces branded generics, generic drugs, active pharmaceutical ingredients (APIs), and nutraceuticals, which it markets in India and international markets. It has a portfolio of approximately 800 brands in India and maintains a presence in over 40 international markets, with the United States being its key focus market. Its offerings include therapies, prescription (Rx) products, and Alkem generics. Its therapy offerings cover multiple medical fields, including anti-infectives, anti-osteoporosis, cardiology, neurology, dermatology, diabetology, gastroenterology, gynecology, oncology, ophthalmology, respiratory care, rheumatology, and urology. The Company’s subsidiaries include Ascend Laboratories (Pty) Ltd, Pharmacor Pty Limited, Alkem Laboratories Corporation, and others. As of 26 May 2026, Alkem Laboratories share price is ₹5,400.50. The stock opened at ₹5,485.00, compared to its previous close of ₹5,404.50. During today's trading session, Alkem Laboratories share price moved in the range of ₹5,388.50 to ₹5,485.00, with an average price of ₹5,436.75 for the day. Looking at its last 52-week, the stock has touched a low of ₹5,388.50 and a high of ₹5,485.00. On the performance front, Alkem Laboratories share price has declined by 5.27% over the last six months and is up 2.13% on a year-on-year basis.
The market capitalization of Alkem Laboratories is ₹64,633 Crs, with a P/E ratio of 26.7 and a dividend yield of 0.83%.